UNASSIGNED: A hallmark of @entity712 ( @entity712 ) is adverse extracellular matrix (ECM) remodeling, which is regulated by the collagen cross-linking enzyme, @entity12553 oxidase ( @entity68845 ). In this study, we evaluate the efficacy of @entity68845 inhibition to prevent adverse left ventricular (LV) remodeling and dysfunction using an experimental model of @entity712 . @entity35 were subjected to surgically induced @entity1284 ( @entity1284 ) by creation of @entity292 ( @entity292 ). A @entity68845 inhibitor, @entity7903 ( @entity7903 ; 100   mg/kg/day), was administered to @entity35 with @entity292 or sham surgery at eight weeks postsurgery. Echocardiography was used to assess progressive alterations in cardiac ventricular structure and function. Left ventricular (LV) catheterization was used to assess alterations in contractility, stiffness, LV pressure and volume, and other indices of cardiac function. The LV ECM alterations were assessed by: (a) histological staining of collagen, (b) protein expression of collagen types I and III, (c) @entity720 assay, and (d) cross-linking assay. @entity68845 inhibition attenuated @entity1284 -induced increases in cardiac stress, and attenuated increases in interstitial myocardial collagen, total collagen, and protein levels of collagens I and III. Both echocardiography and catheterization measurements indicated improved cardiac function post- @entity1284 in @entity7903 treated @entity35 vs. untreated. Inhibition of @entity68845 attenuated @entity1284 -induced decreases in LV stiffness and cardiac function. Overall, our data indicate that @entity68845 inhibition was cardioprotective in the volume overloaded heart.

Cardioprotective effects of XXXX oxidase inhibition against @entity1284 -induced extracellular matrix remodeling.

@entity712 :: ('MESH:D006333', 'Disease') :: ['HF', 'heart failure'] @entity68845 :: ('24914(Tax:10116)', 'Gene') :: ['LOX'] @entity12553 :: ('CHEBI:32568', 'Chemical') :: ['lysyl'] @entity292 :: ('MESH:D005402', 'Disease') :: ['aortocaval fistula', 'ACF'] @entity720 :: ('CHEBI:18095', 'Chemical') :: ['hydroxyproline'] @entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats', 'rats'] @entity7903 :: ('MESH:D000629', 'Chemical') :: ['beta-aminopropionitrile', 'BAPN'] @entity1284 :: ('MESH:D019190', 'Disease') :: ['VO', 'volume overload']
@entity12553 :: (CHEBI:32568,Chemical) :: ['lysyl']
